Healthcare Industry News: IOERT
News Release - October 24, 2006
IntraOp Delivers Mobetron to Nagoya University HospitalFirst IOERT Unit in Japan to Be Installed in the Operating Room
SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced that it has delivered a Mobetron® system to Nagoya University Hospital, in Nagoya, Japan. This is the 18th Mobetron system delivered worldwide, and the second such system delivered to Japan. The Mobetron is a proprietary, mobile electron-beam instrument designed for Intraoperative Electron Radiation Therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. Nagoya University Hospital is one of 80 hospitals in Japan with active IORT programs. However, almost all of these centers transport the patient, in the midst of surgery, from the operating room (OR) to the radiation department to receive the IORT treatment. Although Japan is considered the birthplace of modern IORT, the Nagoya Mobetron unit will be one of the first IOERT systems in the country actually located in the OR.
"Together with our partner in Japan, Chiyoda Technol Corporation, we have been working to introduce the Mobetron's modern IOERT technology to Japan," said Dr. Donald A. Goer, President and Chief Executive Officer of IntraOp. "With the installation of the University of Nagoya, and the planned installation of Gunma Prefecture Hospital early next year, these efforts are beginning to bear fruit. Japan has a rich history of IOERT innovation and adoption. If the Mobetron enables IOERT treatments to be delivered with greater convenience and less cost and disruption, other hospitals in Japan are likely to follow the example of Nagoya and Gunma. Japan could become one of the major markets for our products."
The hospital intends to focus initially on the use of IOERT for pancreatic cancer. In Japan, IOERT is a standard component of the treatment for this disease at many hospitals because the addition of IOERT is significantly more effective in treating this disease than using conventional treatments alone. Published studies from Japanese hospitals that use IOERT to treat this disease show that there is increased tumor control and better survival when used with intent to cure in patients with resectable tumors, and, when used palliatively to treat unresectable tumors, patients experience a higher quality of life with more hospital free survival days. Another site that the University will use the Mobetron for is early stage breast cancer. Breast cancer is becoming an increasingly more common cancer in Japan, and the University of Nagoya will be one of the first Japanese hospitals to offer the benefits of IOERT to this patient population.
Nagoya, Japan's fourth largest city and the capital of Aichi prefecture, is located southwest of Tokyo. The Mobetron at Nagoya University, one of the major cancer treatment centers in the prefecture, is scheduled to begin clinical treatment before the end of the year.
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.